NATIONAL INSTITUTES OF HEALTH MATERIALS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT
NATIONAL INSTITUTES OF HEALTH
MATERIALS COOPERATIVE RESEARCH
AND DEVELOPMENT AGREEMENT
This Materials Cooperative Research and Development Agreement (“M-CRADA”) has been adopted for use by the Institutes and Centers (“ICs”) of the National Institutes of Health (“NIH”) for transfers of essential research material(s) from collaborators (hereinafter “Collaborator Research Material”) not otherwise reasonably available for NIH research. It consists of a copy of the NIH Model M-CRADA, a Signature Page, a Contacts Page, and a Summary Page. The research plan (“Research Plan”) is attached as Appendix A and all changes to this model agreement are collected in Appendix B. Appendices A and B are incorporated herein by reference. This M-CRADA involves no exchange of personnel or of any resources other than as described in Appendix A. This M-CRADA is made under authority of the Federal Technology Transfer Act, 15 U.S.C. § 3710a, and is governed by its terms.
| 1. | Lixte Biotechnology Holdings, Inc., hereinafter referred to as “Collaborator”, agrees to transfer to NIH’s investigator, Richard J. Youle, Ph.D., the following “Collaborator Research Material”: certain compounds proprietary to Collaborator, as listed under Appendix A. |
| 2. | This Collaborator Research Material will be used solely in connection with the Research Plan by NIH’s investigator in his/her laboratory under suitable containment conditions. |
| 2(a). | Are the Collaborator Research Materials of human origin? |
¨ Yes
x No
| 2(b). | If Yes in 2(a), were the Collaborator Research Materials collected according to 45 CFR Part 46, “Protection of Human Subjects?” |
¨ Yes (Please provide Assurance Number: )
¨ No
| 3. | In all oral presentations or written publications concerning the Research Plan, NIH will acknowledge Collaborator’s contribution of this Collaborator Research Material unless requested otherwise. To the extent permitted by law and unless otherwise directed by a court or administrative body of competent jurisdiction, each Party agrees to treat in confidence, for a period of three (3) years from the date of the disclosure, any of the disclosing Party’s written information about this Collaborator Research Material that is stamped “confidential” or any of the disclosing Party’s oral information about this Collaborator Research Material that is identified in writing as being confidential within ten (10) days of the oral disclosure, except for: |
| (a) | information that is publicly known or that becomes publicly available from public sources; |
| (b) | information that has been made available by the disclosing Party to others without a confidentiality obligation; |
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 1 of 10 | Confidential | Revised August 1, 2012 |
| (c) | information that is already known by the receiving Party, or information that is independently created or compiled by the receiving Party without reference to or use of the provided information; or |
| (d) | information that relates to potential hazards or cautionary warnings associated with the production, handling, or use of the subject matter of the Research Plan. |
NIH may publish or otherwise publicly disclose the results of the research, but if Collaborator has given confidential information to NIH such public disclosure may be made only after Collaborator has had thirty (30) days to review the proposed disclosure to determine if it contains any confidential information, except when a shortened time period under court order or the Freedom of Information Act pertains.
| 4. | This Collaborator Research Material represents a significant investment on the part of Collaborator and is considered proprietary to Collaborator. NIH’s investigator therefore agrees to retain control over this Collaborator Research Material, and further agrees not to transfer the Collaborator Research Material to other people not under her or his direct supervision without advance written approval of Collaborator. Collaborator reserves the right to distribute the Collaborator Research Material to others and to use it for its own purposes. |
| 5. | This Collaborator Research Material is provided as a service to the research community. IT IS BEING SUPPLIED TO NIH WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Collaborator makes no representations that the use of the Collaborator Research Material will not infringe any patent or proprietary rights of third parties. It is the intention of NIH that Collaborator not be liable for any claims or damages arising from NIH’s use of the Collaborator Research Material; however, no indemnification is provided or intended. |
| 6. | The NIH shall promptly report to Collaborator in writing each Subject Invention and any patent applications filed thereon resulting from the research conducted under this M-CRADA that is reported to NIH by its employees. Collaborator agrees to keep all information provided to Collaborator confidential until the information is published or the patent issues. “Subject Invention” means any invention, conceived or first actually reduced to practice under this M-CRADA, that is or may be patentable under 35 U.S.C. § 101 or § 161, protectable under 7 U.S.C. § 2321, or otherwise protectable by other types of U.S. or foreign intellectual property rights. |
| 7. | With respect to Government intellectual property rights to any Subject Invention made solely by an NIH employee(s) or jointly with Collaborator for which a patent or other intellectual property application is filed, NIH hereby grants to the Collaborator an exclusive option to elect an exclusive or nonexclusive commercialization license. The license will be substantially in the form of the appropriate model Public Health Service (PHS) license agreement and will fairly reflect the nature of the Subject Invention, the relative contributions of the Parties to the Subject Invention and the M-CRADA, a plan for the development and marketing of the Subject Invention, the risks incurred by Collaborator, and the costs of subsequent research and development needed to bring the Subject Invention to the marketplace. The field of use of the license will not exceed the scope of the Research Plan. This option does not apply to Subject Inventions conceived prior to the effective date of this M-CRADA that are reduced to practice under this M-CRADA, if prior to that reduction to practice, NIH has filed a patent application on the Subject Invention and has licensed it or offered to license it to a third party. |
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 2 of 10 | Confidential | Revised August 1, 2012 |
| 8. | To exercise the option of Paragraph 7, Collaborator must submit a written notice to the PHS Patenting and Licensing Contact identified on the Contacts Information Page (and provide a copy to the NIH Contact for M-CRADA Notices) within three (3) months after the Collaborator receives written notice from NIH that the patent application has been filed. The written notice exercising this option will include a completed “Application for License to Public Health Service Inventions” and will initiate a negotiation period that expires nine (9) months after the exercise of the option. If NIH has not responded in writing to the last proposal by Collaborator within this nine (9) month period, the negotiation period will be extended to expire one (1) month after PHS so responds, during which month Collaborator may accept in writing the final license proposal of NIH. In the absence of Collaborator’s exercise of the option, or upon election of a nonexclusive license, NIH will be free to license the Subject Invention to others. These time periods may be extended at the sole discretion of NIH upon good cause shown in writing by Collaborator. |
| 9. | Pursuant to 15 U.S.C. § 3710a(b)(1)(A), for Subject Inventions made under this M-CRADA by a NIH employee(s) or jointly by such employee(s) and employees of the Collaborator under this M-CRADA, and licensed to Collaborator, the Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the Government. In the exercise of such license, the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C. § 552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. |
| 10. | Pursuant to 15 U.S.C. § 3710a(b)(2), for Subject Inventions made solely by Collaborator employees under this M-CRADA, the Collaborator grants to the Government, a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the Government for research or other Government purposes. |
| 11. | Pursuant to 15 U.S.C. § 3710a(b)(l)(B), if NIH grants an exclusive license to a Subject Invention made wholly by NIH employees or jointly with a Collaborator under this M-CRADA, the Government shall retain the right to require the Collaborator to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the invention in Collaborator’s licensed field of use on terms that are reasonable under the circumstances; or if the Collaborator fails to grant such a license, to grant the license itself. The exercise of such rights by the Government shall only be in exceptional circumstances and only if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator, (ii) the action is necessary to meet requirements for public use specified by Federal regulations, and such requirements are not reasonably satisfied by the Collaborator; or (iii) the Collaborator has failed to comply with an agreement containing provisions described in 15 U.S.C. § 3710a(c)(4)(B). The determination made by the Government under this paragraph is subject to administrative appeal and judicial review under 35 U.S.C. § 203(b). |
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 3 of 10 | Confidential | Revised August 1, 2012 |
| 12. | Any dispute arising under this M-CRADA that is not disposed of by agreement of the Principal Investigators shall be submitted jointly to the signatories of this M-CRADA. If the signatories are unable to jointly resolve the dispute within thirty (30) days after notification thereof, the Assistant Secretary for Health (or his/her designee or successor) shall propose a resolution. Nothing in this article shall prevent any Party from pursuing any additional administrative remedies that may be available and, after exhaustion of such administrative remedies, pursuing all available judicial remedies. |
| 13. | The illegality or invalidity of any provisions of this M-CRADA shall not impair, affect or invalidate the other provisions of this M-CRADA. |
| 14. | Neither this M-CRADA nor any rights or obligations of any Patty hereunder shall be assigned or otherwise transferred by either Party without the prior written consent of the other Party. |
| 15. | All notices pertaining to or required by this M-CRADA will be in writing, signed by an authorized representative of the notifying Party, and delivered by first class, registered, or certified mail, or by an express/overnight commercial delivery service, prepaid and properly addressed to the other Party at the address designated on the Contacts Information Page, or to any other address designated in writing by the other Party. Notices will be considered timely if received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Notices regarding the exercise of license options will be made pursuant to Paragraph 8. Either Party may change its address by notice given to the other Party in the manner set forth above. |
| 16. | By entering into this M-CRADA, the Government does not directly or indirectly endorse any product or service that is or will be provided, whether directly or indirectly related to either this M-CRADA or to any patent or other intellectual property license or agreement that implements this M-CRADA by Collaborator, its successors, assignees, or licensees. Collaborator will not in any way state or imply that the Government or any of its organizational units or employees endorses any product or service. Each Party agrees to provide proposed press releases that reference or rely upon the work under this M-CRADA to the other Party for review and comment at least seven (7) days prior to publication. Either Party may disclose the Summary Page to the public without the approval of the other Party. |
| 17. | Either NIH or Collaborator may unilaterally terminate this M-CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. |
| 18. | This M-CRADA constitutes the entire agreement between the Parties concerning the subject matter of this M-CRADA and supersedes any prior understanding or written or oral agreement. |
| 19. | The construction, validity, performance and effect of this M-CRADA will be governed by U.S. federal law, as applied by the federal courts in the District of Columbia. If any provision in this M-CRADA conflicts with or is inconsistent with any U.S. federal law or regulation, then the U.S. federal law or regulation will preempt that provision. |
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 4 of 10 | Confidential | Revised August 1, 2012 |
| 20. | This M-CRADA shall be effective upon execution by the Parties. The term of this M-CRADA is twelve (12) months from execution. When the Research Plan is completed or twelve (12) months has elapsed, whichever occurs first, or the M-CRADA is terminated, the Collaborator Research Material will be disposed of as directed by Collaborator. |
| 21. | The provisions of Articles 3, 5-12 and 14 shall survive the termination of this M-CRADA. |
SIGNATURES BEGIN ON THE NEXT PAGE
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 5 of 10 | Confidential | Revised August 1, 2012 |
SIGNATURE PAGE
ACCEPTED AND AGREED
By executing this M-CRADA, each Party represents that all statements made herein are true, complete, and accurate to the best of its knowledge. Collaborator acknowledges that it may be subject to criminal, civil, or administrative penalties for knowingly making a false, fictitious, or fraudulent statement or claim.
| FOR NIH (IC): | ||
| /s/ Walter J. Kovoshetz for Dr. S Landis | 9/24/2013 | |
| Signature | Date | |
| WJ Kovoshetz, Deputy Director/NINDS | ||
| Story C. Landis, Ph.D. | ||
| Director, National Institute of Neurological Disorders and Stroke | ||
| FOR COLLABORATOR: | ||
| /s/ John S. Kovach | 10/18/2013 | |
| Signature | Date | |
| John S. Kovach. M.D. | ||
| President, Lixte Biotechnology Holdings, Inc. |
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 6 of 10 | Confidential | Revised August 1, 2012 |
CONTACTS PAGE
M-CRADA Notices
| For IC: | For Collaborator: | |
| Laurie Arrants | John S. Kovach, M.D. | |
| Technology Development Coordinator | 248 Route 25A No. 2 | |
| Building 31, Room 8A52 | East Setauket, NY 11733 | |
| 31 Center Drive, MSC 2540 | Tel: 631 ###-###-#### | |
| Bethesda, MD 20892 | Fax: 631 ###-###-#### | |
| Tel: 301 ###-###-#### | ||
| Fax: 301 ###-###-#### |
Patenting and Licensing
| For NIH: | For Collaborator (if separate from above): | |
| Division Director, Division of Technology | ||
| Development and Transfer | ||
| NIH Office of Technology Transfer | ||
| 6011 Executive Boulevard, Suite 325 | ||
| Rockville, Maryland 20852-3804 | ||
| Tel: 301 ###-###-#### | Tel: | |
| Fax: 301 ###-###-#### | Fax: |
Delivery of Materials Identified In Article 1
For IC:
IC Contact: Richard J. Youle, Ph.D.
IC Address: SNB, Bldg 35, Room 2C-917, 35 Convent Drive, MSC 3704, Bethesda, MD 20892-3704
IC Phone Number: 301 ###-###-####
IC Fax: 301 ###-###-####
IC contact e-mail ***@***
For Collaborator: same as for M-CRADA notices
Collaborator Contact:
Collaborator Address:
Collaborator Phone Number:
Collaborator Fax:
Collaborator contact e-mail:
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 7 of 10 | Confidential | Revised August 1, 2012 |
SUMMARY PAGE
Either party may, without further consultation or permission,
release this summary page to the public.
| TITLE OF M-CRADA: | Characterization of Proprietary Compounds from Lixte Biotechnology Holdings, Inc. | |
| NIH Institute/Center (IC) IC Principal Investigator: | National Institute of Neurological Disorders and Stroke Richard J. Youle, Ph.D. | |
| Collaborator: Collaborator Principal Investigator: | Lixte Biotechnology Holdings, Inc. John S. Kovach, M.D. | |
| TERM OF M-CRADA: | Four (4) years from the Effective Date. |
ABSTRACT OF THE RESEARCH PLAN:
The Surgical Neurology Branch of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health will conduct research characterizing a variety of compounds proprietary to Lixte Biotechnology Holdings, Inc., under a Materials Cooperative Research and Development Agreement. The research will examine the compounds’ potential for anti-cancer activity, reducing neurologic deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases.
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 8 of 10 | Confidential | Revised August 1, 2012 |
APPENDIX A
RESEARCH PLAN
Background
Lixte Biotechnology Holdings, Inc.’s primary emphasis is on developing drugs for cancer but its proprietary compounds also have potential for treating a variety of other diseases. The Surgical Neurology Branch (SNB) has experience in researching brain tumors, neurological brain injury, and inborn diseases affecting the brain, such as Gaucher’s disease, von Hippel-Lindau, and neurofibromatosis type II.
Overall Goal. The SNB would like to examine the Collaborator’s compounds’ potential for anti-cancer activity, reduction of neurologic deficit due to ischemia and brain injury, and stabilization of the catalytic function of misfolded proteins for inborn brain diseases.
Research
The SNB will characterize proprietary compounds from the Collaborator, including but not limited to the following seven:
LB-100, LB-102, LB-113, LB-153, LB-157, LB-201, and LB-205.
Collaborator may provide additional proprietary compounds to the SNB if the parties mutually agree in advance and the transfer is documented in writing.
The SNB may study one or more of the above compounds in in vitro and in vivo (animal models) for the following effects:
| • | promoting anti-cancer activity alone or in combination with standard anti-cancer drugs and/or radiation for the treatment of primary brain tumors and secondary (metastatic) brain tumors; specific cancers may include astrocytic tumors, oligodendroglial tumors, medulloblastoma, meningeal tumors, hemangioblastomas, and brain mestastic tumors |
| • | overcoming or mitigating the physiological phenomenon of multi-drug resistance, particularly of cancer cells to anti-cancer drugs |
| • | reducing neurological deficit due to cerebral ischemia and traumatic brain injury |
| • | stabilizing the catalytic function of misfolded proteins due to genetic variants responsible for inborn diseases affecting the brain, such as Gaucher’s disease, von Hippel-Lindau diseases and neurofibromatosis 2 |
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 9 of 10 | Confidential | Revised August 1, 2012 |
APPENDIX B
EXCEPTIONS OR MODIFICATIONS TO THIS M-CRADA
Additions are noted as underline and deletions are noted as strikeout.
Modify Article 20 as follows:
| Article 20. | This M-CRADA shall be effective upon execution by the Parties. The term of this M-CRADA is forty-eight |
| NIH M-CRADA | Agreement Ref. No. 2013-0167 | MODEL ADOPTED 2006 |
| Page 10 of 10 | Confidential | Revised August 1, 2012 |
